Leaflet DAUNOBLASTINA 20mg powder for solution for injection

Indicated for: leukemia

Route of administration: injectable

Substance: daunorubicin (antineoplastic agent)

ATC: L01DB02 (Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Daunorubicin is a chemotherapy drug used for the treatment of acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, preventing their division.

The medication is administered intravenously and is often used in combination with other chemotherapy drugs to enhance treatment effectiveness. It is effective in inducing remission in patients with acute leukemia.

Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and an increased risk of infections. In rare cases, it may cause cardiac toxicity. Close monitoring is essential during treatment.

Consult your doctor to discuss the benefits and risks of treatment with Daunorubicin. Follow all medical recommendations to minimize associated risks.

General data about DAUNOBLASTINA 20mg

  • Substance: daunorubicin
  • Date of latest medicines list: 01-06-2026
  • Product code: W70910001
  • Concentration: 20mg
  • Pharmaceutical form: powder for solution for injection
  • Quantity: 1
  • Product type: Generic medicine
  • Price: 111.91 RON
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: LATINA PHARMA S.P.A. - ITALIA
  • Holder: PFIZER ROMANIA S.R.L. - ROMANIA
  • Number: 1031/2025/01
  • Shelf life: 3 years

Concentrations available for daunorubicin

  • 20mg
  • 20mg/10ml

Combinations with other substances